✦ LIBER ✦

Clinical trial: extended treatment duration of peginterferon-alpha2b plus ribavirin for 72 and 96 weeks in hepatitis C genotype 1-infected late responders

✍ Scribed by M. NAGAKI; M. SHIMIZU; J. I. SUGIHARA; E. TOMITA; C. SANO; T. NAIKI; K. KIMURA; K. AMANO; T. SAKAI; M. NINOMIYA; T. KOJIMA; N. KATSUMURA; M. FUJIMOTO; H. MORIWAKI

Book ID: 108605671
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 214 KB
Volume: 30
Category: Article
ISSN: 0269-2813
DOI: 10.1111/j.1365-2036.2009.04048.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment extension to 72 weeks of pegin

Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1–infected slow responders

✍ Brian L. Pearlman; Carole Ehleben; Sophia Saifee 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 216 KB 👁 1 views

In hepatitis C virus (HCV) genotype 1 infection, the duration of interferon-based therapy is a critical determinant in achieving sustained virologic response (SVR). Slow or late responders to peginterferon and ribavirin may benefit from an extended treatment course. We sought to determine if therapy

Clinical trial: individualized treatment

Clinical trial: individualized treatment duration for hepatitis C virus genotype 1 with peginterferon-alpha 2a plus ribavirin

✍ K. H. TANG; E. HERRMANN; I. PACHIADAKIS; E. PAULON; N. TATMAN; S. ZEUZEM; N. V. 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 181 KB

Extended treatment duration for treatmen

Extended treatment duration for treatment naïve chronic hepatitis C genotype 1 late viral responders: a meta-analysis comparing 48 weeks vs 72 weeks of pegylated interferon and ribavirin

✍ M. Parikh; A. Singh; G. Sood 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 192 KB

Randomized trial of peginterferon alfa-2

Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virological response

✍ Brian L. Pearlman; Carole Ehleben 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 271 KB 👁 2 views

Randomized trial of peginterferon alfa-2

Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response

✍ Maria Buti; Yoav Lurie; Natalia G. Zakharova; Natalia P. Blokhina; Andrzej Horba 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 197 KB 👁 2 views

The benefit of extending treatment duration with peginterferon (PEG-IFN) and ribavirin (RBV) from 48 weeks to 72 weeks for patients with chronic hepatitis C genotype 1 infection has not been well established. In this prospective, international, open-label, randomized, multicenter study, 1,428 treatm